The largest community of pharma leaders

 KalVista Pharmaceuticals Announces Changes to Board of Directors

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–$KALV–KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Martin Edwards has been appointed and Richard H. Aldrich is resigning from the Company’s Board of Directors. Both changes are part of a planned transition and are effective immediately. “Rich has been an integral part of KalVista since…


Recent Articles